 |
|
|
| |
ACTG 5381: Virologic and Resistance Outcomes
After Switch to TLD for Failing 1st or 2nd Line ART
|
| |
| |
CROI 2024 March 3-6 Denver
Carole L. Wallis1, Caitlyn McCarthy2, Catherine Godfrey3, Sarita Shah4, Cissy Kityo5, Urvi M. Parikh6, Gary Maartens7, Isaac Tsikhutsu8, Fatma Some9, Samuel Pierre10, Yvetot Joseph10, Charles W. Flexner11, Michael D. Hughes2, John W. Mellors6, for the ACTG A5381/The Hakim Study team
1Lancet Laboratories and BARC SA, Johannesburg, South Africa, 2Harvard T.H. Chan School of Public Health, Boston, MA, USA, 3Global Health Security and Diplomacy/PEPFAR, US Department of State, Washington DC, USA, 4Emory University, Atlanta, GA, USA, 5Joint Clinical Research Centre, Kampala Uganda, 6University of Pittsburgh, Pittsburgh, PA, USA, 7University of Cape Town, Cape Town, South Africa, 8, Kenya Medical Research Institute/Walter Reed Project Clinical Research Center, Kericho, Kenya,
9Moi University Clinical Research Center, Eldoret, Kenya, 10GHESKIO (Haitian Group for the Study of Kaposi’s Sarcoma and Opportunistic Infections), Port-au-Prince, Haiti, 11Johns Hopkins University, Baltimore, MD, USA
|
| |
|
|
|
|
|
